I have never believed that NVIV would bring its products to market. I always assumed the company would be bought out. The obstacle to any sale – the former CEO – is no longer relevant.
I believe the outlook for this company being purchased is extremely high. How much is worth is anybody’s guess. My opinion is $5-$10 today, significantly more if the scaffolding trials are successful. While I don’t believe the scaffolding technology would have a financial impact on the bottom line of a major pharmaceutical company, the public relations image of the company that could bring that technology to those in need will be nothing short of astonishing.
Thank you---I also believe that Mr; Astrue was brought in as "interim" CEO just for the purpose of estimating the net worth of In Vivo's "pipeline" (scaffold, hydrogel, dura patch etc) and then to entertain "buyout" offers--this especially makes sense when you consider Mr. Astrue's multiple contacts/government experience when it comes to the biotech industry. I think this maybe benefical to both to the company (having enough funds to go forward with development of the pipeline products) and also shareholders (no reverse dilutions of the stock etc)